CIK 0001806952
- Non-accelerated filer
- Smaller reporting company
Lyell Immunopharma, Inc.
Sign in to watch- Ticker
- LYEL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 833006753
- Phone
- +1 650-695-0677
- Business address
- 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $49,999,983
- in 2 filings
- Open-market sales, last 90 days
- $215,781
- in 9 filings
Net +$49,784,202. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 41 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-29 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other disposition | −76,000 | 2,857,500 | ||
| 2026-06-15 | Innovative Cellular Therapeutics Holdings Ltd 10% owner | Other disposition | −66,500 | 2,933,500 | ||
| 2026-06-10 | Bachleda Mark Director | Grant or award · Option (right to buy) | +9,250 | 9,250 | ||
| 2026-06-10 | NABEL ELIZABETH G Director | Grant or award · Option (right to buy) | +9,250 | 9,250 | ||
| 2026-06-10 | Klausner Richard Director | Grant or award · Option (right to buy) | +9,250 | 9,250 | ||
| 2026-06-10 | Ramachandra Sumant Director | Grant or award · Option (right to buy) | +9,250 | 9,250 | ||
| 2026-06-10 | FRIEDMAN CATHY Director | Grant or award · Option (right to buy) | +9,250 | 9,250 | ||
| 2026-06-10 | BRAWLEY OTIS W Director | Grant or award · Option (right to buy) | +9,250 | 9,250 | ||
| 2026-06-10 | RIEFLIN WILLIAM JL Director | Grant or award · Option (right to buy) | +9,250 | 9,250 | ||
| 2026-06-10 | Shook David Chief Medical Officer | Sale | −1,977 | $12.64 | $25K | 20,923 |
| 2026-05-11 | Bulis Veronica Sanchez VP, Corporate Controller | Sale | −217 | $18.91 | $4K | 15,420 |
| 2026-05-11 | Lee Gary K. Chief Scientific Officer | Sale | −130 | $18.92 | $2K | 17,808 |
| 2026-05-11 | Hill Stephen J. Chief Operating Officer | Sale | −89 | $18.92 | $2K | 17,894 |
| 2026-05-11 | Seely Lynn President and CEO | Sale | −388 | $18.91 | $7K | 73,878 |
| 2026-03-09 | Shah Smital Chief Fin. and Bus. Officer | Grant or award · Option (right to buy) | +140,000 | 140,000 | ||
| 2026-03-06 | ARCH Venture Partners IX, LLC 10% owner | Purchase | +488,090 | $25.61 | $12.5M | 1,426,528 |
| 2026-03-06 | ARCH Venture Fund XIII, L.P. 10% owner | Purchase | +488,090 | $25.61 | $12.5M | 1,426,528 |
| 2026-02-11 | Lee Gary K. Chief Scientific Officer | Sale | −1,671 | $23.39 | $39K | 16,938 |
| 2026-02-11 | Hill Stephen J. Chief Operating Officer | Sale | −1,236 | $23.39 | $29K | 17,795 |
| 2026-02-11 | Seely Lynn President and CEO | Sale | −7,455 | $23.39 | $174K | 74,266 |
Page 2 of 8 · 156 trades